SYNTIMMUNE
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumberg founded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts.
SYNTIMMUNE
Industry:
Biotechnology Emergency Medicine Health Care Medical Pharmaceutical
Founded:
2013-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.syntimmune.com
Total Employee:
1+
Status:
Active
Contact:
617-206-4220
Email Addresses:
[email protected]
Total Funding:
76 M USD
Technology used in webpage:
SPF Amazon ReCAPTCHA Amazon Route 53 Amazon CloudFront DMARC
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montrรฉal and Lรฉvis.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Saphtx
Saphtx develops protein-based therapeutic strategies for a wide range of diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series B - Syntimmune
Partners Innovation Fund
Partners Innovation Fund investment in Series B - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series B - Syntimmune
Partners Innovation Fund
Partners Innovation Fund investment in Series A - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series A - Syntimmune
Apple Tree Partners
Apple Tree Partners investment in Series A - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series A - Syntimmune
Partners Innovation Fund
Partners Innovation Fund investment in Series A - Syntimmune
Apple Tree Partners
Apple Tree Partners investment in Series A - Syntimmune
Baxalta Ventures
Baxalta Ventures investment in Series A - Syntimmune
Official Site Inspections
http://www.syntimmune.com
- Host name: server-52-85-132-77.iad50.r.cloudfront.net
- IP address: 52.85.132.77
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Syntimmune"
SystImmune - Crunchbase Company Profile & Funding
Organization. SystImmune . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. SystImmune is a biotechnology company. ... SystImmune is a biopharmaceutical company. It is โฆSee details»
Systimmune Company Profile 2024: Valuation, โฆ
Systimmune General Information Description. Operator of a biopharmaceutical company intended to develop antibody-based drug therapies. The company aims to offer novel therapeutic bi-specific, and multi-specific antibodies, as well as โฆSee details»
Careers - Operation - Chief of Staff to the CEO - SystImmune
SystImmune Inc. is a dynamic clinical-stage bio-pharmaceutical company headquartered in Redmond, WA. Our mission is to revolutionize cancer treatment by developing breakthrough โฆSee details»
SystImmune - LinkedIn
SystImmune | 13,433 followers on LinkedIn. Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through โฆSee details»
SystImmune Information - RocketReach
Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri โฆSee details»
Systimmune, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
100 Clinical Results associated with Systimmune, Inc. Login to view more data. ... The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as โฆSee details»
Systimmune - Company Profile - Tracxn
Nov 27, 2024 SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023PR Newswire โข Oct 21, 2023 โข Systimmune Baili Announces Clinical Trial Collaboration to โฆSee details»
Systimmune - VentureRadar
Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug โฆSee details»
SystImmune - Contacts, Employees, Board Members, Advisors
SystImmune is a biotechnology company. Unlock even more features with Crunchbase ProSee details»
Syntimmune Company Profile 2024: Valuation, โฆ
Information on acquisition, funding, cap tables, investors, and executives for Syntimmune. Use the PitchBook Platform to explore the full profile.See details»
SystImmune, Inc. Announces FDA Clearance of IND Application for โฆ
Redmond, WA โ October 14th, 2024 โ SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has โฆSee details»
SystImmune Company Profile - Office Locations, Competitors
SystImmune has 5 employees at their 1 location and $76 m in total funding,. See insights on SystImmune including office locations, competitors, revenue, financials, executives, โฆSee details»
SystImmune, Inc. to Present New Data from Oncology Programs at โฆ
May 1, 2023 ๏ปฟ SystImmune Programs Profiled at ASCO About SI-B001 The company has developed SI-B001, also known as izalontamab, an EGFR×HER3 bispecific antibody that can โฆSee details»
News - SystImmune, Inc. Announces the Appointment of Dr.
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer. Redmond, Washington May 23 rd, 2024. SystImmune, Inc., a pioneering clinical-stage โฆSee details»
SystImmune, Inc. Announces FDA Clearance of IND Application for โฆ
REDMOND, Wash., Nov. 8, 2024 /PRNewswire/ -- SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) โฆSee details»
SystImmune, Inc. Announces Upcoming Presentation at the2024 โฆ
Redmond, WA โ November 26 th, 2024 โ SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an upcoming poster presentation on BL-M11D1, an โฆSee details»
SystImmune, Inc. Announces Upcoming Presentation at the 2024 โฆ
REDMOND, Wash., Nov. 26, 2024 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an upcoming poster presentation on BL โฆSee details»
SystImmune, Inc. Announces Upcoming Presentation at the
REDMOND, Wash., Nov. 26, 2024 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an upcoming poster presentation on BL โฆSee details»
News - SystImmune, Inc. to Present Updated BL-B01D1 Data in โฆ
Redmond, WA โ December10 th, 2024 โ SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that a poster for BL-B01D1, a potentially first-in โฆSee details»